戻る Agenda
The EU HTA Procedure: Ensuring Timely Access to OMPs and ATMPs
Session Chair(s)
Matias Olsen, MA
Senior Manager, Public Affairs & Policy
European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Belgium
Objectives Inform attendees about the new EU HTA procedure and discuss how it can speed up access to innovative therapies (e.g. OMPs and ATMPs), the importance of involving all relevant stakeholders and interactions between developers and the assessors, the procedures for addressing multiple and competing comparators requests from Member States and the possible methodological approaches for OMPs and ATMPs. Overview The panel will discuss the challenges and opportunities of the new EU HTA system, especially OMPs and ATMPs. Panelists will discuss whether the proposed “one-stop-shop” will be achievable and what will be needed to ensure the success of EU HTA.
Learning Objective : Inform attendees about the new EU HTA procedure and discuss: How it can speed up access to innovative therapies, e.g. OMPs and ATMPs; The importance of involving all relevant stakeholders and interactions between developers and the assessors; The procedures for addressing multiple and competing comparators requests from Member States and the possible methodological approaches for OMPs and ATMPs.
Speaker(s)
Ana Palma, PharmD
Sobi, Belgium
Senior Director Global Head Patient Access & Policy
How can the new Procedure Speed up Patient Access Across all Members States?
François Houyez
European Organisation for Rare Diseases (EURORDIS), France
Treatment Information and Access Director, Health Policy Advisor